CY1121562T1 - Anti-fxi αντισωματα και μεθοδοι χρησης - Google Patents

Anti-fxi αντισωματα και μεθοδοι χρησης

Info

Publication number
CY1121562T1
CY1121562T1 CY20191100401T CY191100401T CY1121562T1 CY 1121562 T1 CY1121562 T1 CY 1121562T1 CY 20191100401 T CY20191100401 T CY 20191100401T CY 191100401 T CY191100401 T CY 191100401T CY 1121562 T1 CY1121562 T1 CY 1121562T1
Authority
CY
Cyprus
Prior art keywords
fxi
monoclonal antibodies
antibodies
methods
fxiia
Prior art date
Application number
CY20191100401T
Other languages
English (en)
Inventor
Andras Gruber
Erik I. Tucker
David Gailani
Original Assignee
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University filed Critical Oregon Health & Science University
Publication of CY1121562T1 publication Critical patent/CY1121562T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Στο παρόν αποκαλύπτονται μονοκλωνικά αντισώματα ειδικά για παράγοντα XI (fXI) που αποτρέπουν ενεργοποίηση του fXI από παράγοντα XIIa (fXIIa). Τα μονοκλωνικά αντισώματα είναι γενικά fXI αντισώματα, ικανά σύνδεσης όλων των ειδών θηλαστικού που εξετάζονται. Τα αντι-fXI μονοκλωνικά αντισώματα παρατείνουν χρόνο πήξης σε πλάσματα θηλαστικού. Επιπλέον, χορήγηση των fXI μονοκλωνικών αντισωμάτων που αποκαλύπτονται στο παρόν, έχει σαν αποτέλεσμα παρεμπόδιση θρόμβωσης χωρίς μεταβολή αιμόστασης σε ζωικά μοντέλα θρόμβωσης. Έτσι, παρέχονται στο παρόν μονοκλωνικά αντισώματα ειδικά για το fXI που αναστέλλουν ενεργοποίηση του fXI από fXIIa, συνθέσεις και ανοσοπροϊόντα σύζευξης που περιλαμβάνουν τέτοια αντισώματα και μέθοδοι χρήσης αυτών.
CY20191100401T 2008-12-18 2019-04-10 Anti-fxi αντισωματα και μεθοδοι χρησης CY1121562T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13859008P 2008-12-18 2008-12-18
PCT/US2009/068768 WO2010080623A2 (en) 2008-12-18 2009-12-18 Anti-fxi antibodies and methods of use

Publications (1)

Publication Number Publication Date
CY1121562T1 true CY1121562T1 (el) 2020-05-29

Family

ID=42317079

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100401T CY1121562T1 (el) 2008-12-18 2019-04-10 Anti-fxi αντισωματα και μεθοδοι χρησης

Country Status (15)

Country Link
US (3) US8388959B2 (el)
EP (1) EP2373691B1 (el)
AU (1) AU2009335643B2 (el)
CA (1) CA2747519C (el)
CY (1) CY1121562T1 (el)
DK (1) DK2373691T3 (el)
ES (1) ES2720594T3 (el)
HR (1) HRP20190605T1 (el)
HU (1) HUE042940T2 (el)
LT (1) LT2373691T (el)
PL (1) PL2373691T3 (el)
PT (1) PT2373691T (el)
SI (1) SI2373691T1 (el)
TR (1) TR201904662T4 (el)
WO (1) WO2010080623A2 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160046728A1 (en) * 2007-10-31 2016-02-18 Bioxodes Sa Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands
ES2720594T3 (es) * 2008-12-18 2019-07-23 Univ Oregon Health & Science Anticuerpos anti-fXI y métodos de uso
CN102600471A (zh) * 2012-02-15 2012-07-25 中国人民解放军军事医学科学院微生物流行病研究所 一种败血症治疗的靶点
PL2847228T3 (pl) * 2012-05-10 2019-03-29 Bayer Pharma Aktiengesellschaft Przeciwciała zdolne do wiązania się z czynnikiem krzepnięcia XI i/lub jego aktywowaną postacią, czynnikiem Xla oraz ich zastosowanie
US9574013B2 (en) 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
WO2016109774A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
KR20180104036A (ko) 2016-01-22 2018-09-19 머크 샤프 앤드 돔 코포레이션 항-응고 인자 xi 항체
US11059905B2 (en) 2016-03-23 2021-07-13 Prothix B.V. Monoclonal antibodies against the active site of factor XI and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
SG10202103120UA (en) * 2016-06-14 2021-05-28 Merck Sharp & Dohme Anti-coagulation factor xi antibodies
PE20191319A1 (es) * 2016-09-20 2019-09-24 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos
US11168147B2 (en) * 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
US11958911B2 (en) * 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN108409863B (zh) 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
JP2021503891A (ja) 2017-11-22 2021-02-15 ノバルティス アーゲー 抗第ＸＩ／ＸＩａ因子抗体に対する反転結合剤およびそれらの使用
JP2021534098A (ja) * 2018-08-09 2021-12-09 上海仁会生物制▲やく▼股▲ふん▼有限公司Shanghai Benemae Pharmaceutical Corporation 抗第ｘｉ因子抗体
CA3125303A1 (en) * 2019-01-21 2020-07-30 Aronora Inc. Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effects and uses thereof
CN113474374A (zh) 2019-04-16 2021-10-01 四川科伦博泰生物医药股份有限公司 抗FXI/FXIa抗体及其用途
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
JP2023532251A (ja) * 2020-07-02 2023-07-27 北京拓界生物医薬科技有限公司 抗ＦＸＩ／ＦＸＩａ抗体、その抗原結合断片と医薬用途
WO2022002233A1 (zh) 2020-07-03 2022-01-06 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白
US20230131338A1 (en) 2021-10-22 2023-04-27 Regeneron Pharmaceuticals, Inc. Factor xi a2 domain-binding antibodies and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US8574849B2 (en) * 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
DK2222707T3 (en) * 2007-11-21 2016-04-11 Univ Oregon Health & Science Monoclonal anti-factor XI antibodies and method of use thereof
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
CA2743864A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
ES2720594T3 (es) * 2008-12-18 2019-07-23 Univ Oregon Health & Science Anticuerpos anti-fXI y métodos de uso
MA34330B1 (fr) 2010-05-27 2013-06-01 Merck Sharp & Dohme Activateurs de guanylate cyclase soluble
EP2687210A1 (de) 2010-06-25 2014-01-22 Bayer Intellectual Property GmbH Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
CA2833698A1 (en) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
JP5976788B2 (ja) 2011-05-06 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリジンおよびイミダゾピリダジンならびにそれらの使用
BR112014004569A2 (pt) 2011-09-01 2017-06-13 F. Hoffmann-La Roche Ag composto da fórmula i, métodos para tratar condição inflamatória, artrite reumatoide, asma e distúrbio imune, composição farmacêutica e uso do composto
MX348470B (es) 2011-09-02 2017-06-13 Bayer Ip Gmbh Pirimidinas anilladas sustituidas y uso de las mismas.
PL2847228T3 (pl) 2012-05-10 2019-03-29 Bayer Pharma Aktiengesellschaft Przeciwciała zdolne do wiązania się z czynnikiem krzepnięcia XI i/lub jego aktywowaną postacią, czynnikiem Xla oraz ich zastosowanie

Also Published As

Publication number Publication date
AU2009335643B2 (en) 2014-05-29
CA2747519C (en) 2019-04-02
EP2373691A2 (en) 2011-10-12
ES2720594T3 (es) 2019-07-23
US9637550B2 (en) 2017-05-02
US8388959B2 (en) 2013-03-05
AU2009335643A1 (en) 2011-07-07
PT2373691T (pt) 2019-05-08
HRP20190605T1 (hr) 2019-05-31
LT2373691T (lt) 2019-05-27
TR201904662T4 (tr) 2019-05-21
US20130129745A1 (en) 2013-05-23
DK2373691T3 (en) 2019-04-15
EP2373691B1 (en) 2019-01-23
US8940883B2 (en) 2015-01-27
EP2373691A4 (en) 2012-10-31
US20110250207A1 (en) 2011-10-13
PL2373691T3 (pl) 2019-07-31
US20150093395A1 (en) 2015-04-02
SI2373691T1 (sl) 2019-05-31
WO2010080623A3 (en) 2010-11-18
CA2747519A1 (en) 2010-07-15
HUE042940T2 (hu) 2019-07-29
WO2010080623A2 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
CY1121562T1 (el) Anti-fxi αντισωματα και μεθοδοι χρησης
CY1125705T1 (el) Πρωτεϊνες προσδεσης καλλικρεϊνης πλασματος
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
CY1114509T1 (el) Αναστολεις της ns5a toy hcv
CY1117650T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1118014T1 (el) Aνti-il-23 αντισωματα
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
CY1121419T1 (el) Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CY1115078T1 (el) Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
DK2260862T3 (da) Sammensætninger og fremgangsmåder til behandling af tumorer der præsenterer survivin-antigener
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
CY1112798T1 (el) Ενωσεις διαρυλυδαντοϊνης
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
CY1113819T1 (el) Σκευασματα για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις